Introduction
============

Urothelial cell carcinoma (UCC) is the second leading cause of death among malignancies of the genitourinary tract system in the US. Invasive UCC of the upper urinary tract has a poor prognosis. The 5-year survival rates of patients with stage T2 and T3 disease are respectively 73% and 40%, and the median survival for patients with stage T4 disease is only 6 months [@B1]. There are several types of UCC (bladder, renal pelvis, and ureter carcinomas) with similar histologic features, and approximately 90% of bladder cancers are of the UCC type. In Taiwanese, mortality rates of bladder cancer ranked 13^th^ among all cancer deaths for females and 12^th^ among males [@B2]. There are many environmental risk factors reported to be correlated with susceptibility to bladder cancer, such as smoking, occupational exposure to aromatic amines, and arsenic exposure in drinking water [@B3]. In addition, increasing evidence regarding the impacts of genetic factors on the risk or clinicopathologic development of UCC was reported [@B4]-[@B6].

Dopamine, an important neurotransmitter, plays a crucial role in inducing cell growth, motility, and gene expression by activating specific dopamine receptors (DRs). DRs are a class of G-protein-coupled receptors and are important in the nervous system. DRs are divided into the D1-like class (DRD1 and DRD5) and D2-like class (DRD2, DRD3, and DRD4). These receptors work antagonistically to modulate the synthesis of cyclic adenosine monophosphate (cAMP) and activity of protein kinase A (PKA) [@B7]. Dysregulated dopamine secretion or inactivation of DRs was reported to correlate with various neurological diseases such as schizophrenia and Parkinson\'s disease [@B8]. In addition to the traditional function of DRs in neurological diseases, among DRs, DRD2 especially was reported to be overexpressed in different cancer types, including cervical, lung, pituitary, colon, and gastric cancers and to be correlated with poor prognoses of these cancers [@B7], [@B9]. Moreover, blocking DRD2 was shown to suppress proliferation and induce apoptosis of both cancer cells and cancer stem cells [@B7], [@B10]. These findings suggest an association between DRD2 and several cancers. Although the expression and the effects of DRD2 inhibition were reported in several types of cancer, the correlation between the expression and genetic alteration of DRD2 with the risk of UCC has not been investigated yet.

Among DNA sequence variations, single-nucleotide polymorphisms (SNPs) are the most common event, and this kind of genetic variation may regulate gene expressions to further affect the susceptibility to diseases such as cancers [@B11], [@B12]. A number of SNPs in the gene encoding DRD2 were described. Three SNPs, rs1799732 (DRD2 -141C\>del), rs6277 (DRD2 957C\>T), and rs1800497 (DRD2 TaqIA), are reported to affect the expression and function of this protein [@B13], [@B14]. Moreover, because rs1079597 (DRD2 TaqIB) is closer to the regulatory and structural coding regions (5\' region) of the gene, it is believed to play a role in transcriptional regulation [@B15]. These DRD2 SNPs were reported to be associated with the risk of diseases such as Parkinson\'s disease [@B16], colorectal cancer [@B17], and lung cancer [@B18]. Moreover, rs1800497 were also reported to be associated with adenoma recurrence in the Polyp Prevention Trial [@B19] and may increase the risk of smoking among cancer patients [@B20]. Until now, to the best of our knowledge, the effects of *DRD2* gene variants on UCC remain poorly investigated. In this study, we explored the contributions of four *DRD2* SNPs, rs1799732, rs1079597, rs6277, and rs1800497, which are respectively located on the promoter, intron 1, exon 7, and 3\' untranslated region (UTR) downstream regions, to UCC susceptibility and clinicopathological characteristics.

Materials and methods
=====================

Study subjects, ethics, and consent
-----------------------------------

In the current study, 369 UCC patients (241 men and 128 women; mean age = 68.81 ± 11.77 years) were consecutively recruited from the Taichung Veterans General Hospital, Taichung, Taiwan. For the control groups, 738 healthy control (482 men and 256 women; mean age = 61.19 ± 5.60 years) who had neither self-reported history of cancer of any sites. For the UCC patients, the clinical staging of the UCC patients were staged at the time of diagnosis following the tumor/node/metastasis staging system of the American Joint Committee on Cancer (AJCC) [@B21]. The study subjects were investigated by interviewer-administered questionnaires containing questions involving demographic characteristics to collect their personal information and characteristics. 37.8 % and 30.4 % of the recruited control subjects and UCC patients had a smoking habit. The study protocol was approved by the Institutional Review Board of Taichung Veterans General Hospital, and the informed written consent was obtained from each individual before the initiation of the study. Whole-blood specimens collected from controls and UCC patients were placed in tubes containing ethylenediaminetetraacetic acid (EDTA), immediately centrifuged, and then stored at -80 °C.

Genomic DNA extraction and DRD2 polymorphism selection
------------------------------------------------------

To acquire genomic DNA, preserved blood in EDTA anti-coagulated tubes was extracted using a QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer\'s protocols. We dissolved DNA in pH 7.8 TE buffer containing 10 mM Tris and 1 mM EDTA and then quantified it by a measurement of OD260. The final preparation was stored at -20 °C and was used to act as templates for the PCR. In total, four SNPs in DRD2 were selected from the International HapMap Project data for this study. We included -141C\>del (rs1799732) in the promoter region; rs1079597 (TaqIB) and rs6277 (957C\>T), which are respectively located in intron 1 and exon 7; and rs1800497 (TaqIA) located downstream of the 3\' UTR. We selected these SNPs for this study since these SNPs were reported to affect the expression and binding potential of DRD2 and also correlated with the susceptibility of colorectal and lung cancers [@B14], [@B17], [@B18], [@B22].

Genotyping of DRD2 SNPs
-----------------------

Allelic discrimination of DRD2 rs1799732 (assay ID: C\_\_33641686_10), rs1079597 (assay ID: C\_\_\_2278884_10 ), rs6277 (assay ID: C\_\_11339240_10 ), and rs1800497 (assay ID: C\_\_\_7486676_10) SNP was assessed using the TaqMan SNP Genotyping Assay with an ABI StepOnePlus™ Real-Time PCR System (Thermo Fisher Scientific, MA) and further evaluated with SDS version 3.0 software (Applied Biosystems, Foster City, CA) as described previously [@B23].

Statistical analysis
--------------------

Fisher\'s exact test and the Mann-Whitney U-test were used to evaluate differences in age, gender, and distributions of demographic characteristic between the controls and patients with UCC. The odds ratios (ORs) and 95% confidence intervals (CIs) of associations of genotype frequencies and clinical pathological characteristics with UCC risk were estimated by multiple logistic regression models. *p*\<0.05 was considered statistically significant. Data were analyzed with SAS statistical software (vers. 9.1, 2005; SAS Institute, Cary, NC).

Results
=======

Demographic and lifestyle characteristics of UCC patients are shown in Table [1](#T1){ref-type="table"}. Comparing to the healthy controls, there was no significant difference in the distribution of sex, but significantly different distributions of age (*p* \< 0.001) and tobacco use (*p* = 0.014) were found. To reduce the possible interference of confounding variables, adjusted ORs (AORs) with 95% CIs were estimated by multiple logistic regression models after controlling for other covariates in each comparison.

Genotype distributions of polymorphisms in the promoter region (rs1799732, DRD2 -141C\>Del), intron 1 (rs1079597, DRD2 TaqIB), exon 7 (rs6277, DRD2 957C\>T), and the 3\' UTR downstream (rs1800497, DRD2 TaqIA) between patients and controls are presented in Table [2](#T2){ref-type="table"}. Genotypic distributions of *DRD2* rs1799732, rs1079597, rs6277, and rs1800497 in the control group conformed to Hardy-Weinberg equilibrium (p=0.846, χ2 value: 0.038; p=0.098, χ2 value: 2.750; p=0.277, χ2 value: 1.181 and p=0.423, χ2 value: 0.641, respectively). The distributions of DRD2 genotypes revealed that the most frequent alleles were heterozygous G/A and C/T for the rs1079597 and rs1800497 loci, respectively, and homozygous Ins/Ins and C/C for the rs1799732 and rs6277 loci, respectively. After adjusting for several variables, we found that subjects with heterozygous C/T of the DRD2 rs6277 polymorphism had a 0.405-fold (95% CI: 0.196\~0.837; *p*=0.015) significantly lower risk of developing UCC compared to those with C/C homozygotes. There were no significant differences in genotype distributions between UCC patients and the controls for the rs1799732, rs1079597, or rs1800497 SNPs.

Impacts of the DRD2 polymorphic genotype on the clinicopathological development of UCC including clinical statuses of cancer stage, primary tumor size, lymph node involvement, distant metastasis, and histologic grade were further evaluated, and results are shown in Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}. We classified UCC patients into two subgroups, including patients who had the homozygous wild-type (WT) alleles or who had at least one polymorphic allele. Among 124 younger UCC patients under 65 years of age, those carrying at least 1 polymorphic T allele of DRD2 rs1800497showed a significantly higher risk of having a muscle-invasive tumor (OR=2.270, 95% CI: 1.060\~4.860, *p*=0.033) than those carrying the WT gene (Table [3](#T3){ref-type="table"}). Moreover, DRD2 rs1799732 promoter polymorphisms presented significant differences with clinical stage (OR=2.585, 95% CI: 1.066\~6.264, *p*=0.032) and tumor size (OR=2.778, 95% CI: 1.146\~6.735, *p*=0.021) in female UCC patients with at least one DRD2-141Del polymorphism (Table [4](#T4){ref-type="table"}).

To further dissect the clinical significance of DRD2 in UCC, bladder UCC cases were analyzed from TCGA dataset. Significantly higher DRD2 transcripts were observed in tumors of patients with advanced clinical stage (stage III) and tumor metastasis compared to patients with early stages (stage I+II) and without tumor metastasis (*p*\<0.05; Fig. [1](#F1){ref-type="fig"}A, B). Moreover, relative levels of DRD2 transcripts were higher in patients with larger tumors (T3-T4 status) than in patients with smaller tumors (T0-T2 status) in a marginal trend toward significance (*p*=0.053; Fig. [1](#F1){ref-type="fig"}C). The Kaplan-Meier plot revealed poor overall survival of patients with high DRD2 expression (*p*=0.0209; Fig. [1](#F1){ref-type="fig"}D). Furthermore, 165 bladder UCC cases were also analyzed from the Gene Expression Omnibus (GEO) database (GSE13507), and we found that significantly higher DRD2 was observed in tumors with muscle invasion compared to non-muscle-invasive tumors (*p*=0.0346; Fig. [1](#F1){ref-type="fig"}E). Most importantly, patients who had DRD2^high^ tumors had shorter disease-specific survival times compared with those who had DRD2^low^ tumors (*p*=0.0291; Fig. [1](#F1){ref-type="fig"}F). Taken together, the above clinical data indicated that upregulation of DRD2 is a critical event in promoting UCC progression and suggest that DRD2 variants may alter DRD2 expression and subsequently modulate UCC progression.

Discussion
==========

There are several reports indicating elevated DRD2 expression in cancer cells compared to normal cells in several cancer types, and DRD2 overexpression correlates with an advanced stage and stemness of cancer and a poor prognosis of patients [@B7], [@B9], [@B24]. Moreover, antagonizing DRD2 signaling either by DRD2 antagonists, such as thioridazine and trifluoperazine, or genetic depletion show the proapoptotic, antimetastatic, antiangiogenic, and anticancer stem cell properties in several tumor types [@B7], [@B10], [@B25]. At present, DRD2 genetic variants have been reported to affect the expression and function of DRD2 and to be correlated with the susceptibility and clinicopathologic development of cancers such as colon and lung cancers, and pituitary adenomas [@B17], [@B18], [@B22], [@B26]. The present study, for the first time to our knowledge, investigated the occurrence of the rs1800497 (TaqIA), rs1079597 (TaqIB), rs6277 (957C\>T), and rs1799732 (-141C\>Del) polymorphisms of the DRD2 gene in a Taiwanese population, and their possible clinical relevance in patients with UCC. Moreover, we also analyzed the prognostic significance of DRD2 in UCC using the GEO and TCGA databases.

As to the correlation between DRD2 SNPs and risk of UCC, we observed that the rs6277 C/T heterozygous polymorphism was associated with a significantly lower risk of developing UCC compared to the rs6277 C/C homozygous polymorphism. This result suggested that the DRD2 957T allele is a protective factor in UCC. The 957C\>T polymorphism is located in the exon 7 region. Although this SNP codes for the silent change (proline to proline) at codon 319, it might still play a role in messenger (m)RNA stability. It was reported that the T allele variant is associated with alterations of mRNA folding, and decreases in mRNA stability and translation in vitro [@B22]. Moreover, Hirvonen et al. further indicated that subjects carrying the 957T allele had markedly lower striatal DRD2 availability (binding potential, BP) [@B27]. We speculated that the rs6277 T allele, associated with lower DDR2 expression, may influence the tumorigenesis of UCC. Actually, a DRD2 expression analysis in bladder cancer from TCGA and GEO databases revealed that patients who had high DRD2-expressing tumors had shorter overall and disease-specific survival times and advanced clinical stage and metastatic tumors compared to those with low DRD2-expressing tumors. These results indicated that the DRD2 expression level might affect the progression of UCC.

Moreover, our results showed that female individuals carrying at least one DRD2 -141Del polymorphism had a higher risk of an advanced clinical stage and a larger tumor. This DRD2 rs1799732 polymorphism was also reported to be associated with recurrence of adenomas and risk of colon and lung cancers [@B17]-[@B19]. The DRD2 rs1799732 polymorphism comprises a C deletion in the 5\' UTR of DRD2, is considered a functional polymorphism, and is associated with a 20%\~40% reduction in basal levels of receptor expression [@B28]. However, this result was not further demonstrated in a subsequent study [@B29]. Hence, the influence of the DRD2 rs1799732 polymorphism on DRD2 expression should be further investigated in the future. Furthermore, our results showed that individuals under the age of 65 years carrying at least one polymorphic T allele of DRD2 rs1800497 had a higher risk of having muscle-invasive tumors. The rs1800497 TT genotype was also reported to be associated with advanced adenoma recurrence in the Polyp Prevention Trial [@B19]. The rs1800497 SNP is 10 kb downstream from the DRD2 gene and is located in the neighboring ankyrin repeat and kinase domain containing 1 (ANKK1) gene where it causes an amino acid substitution (Glu713Lys) [@B30]. A previous study indicated that the T allele of rs1800497 was associated with reduced BP of DRD2 in healthy subjects. In contrast to healthy subjects, the T allele was associated with increased BP of DRD2 in patients with a major depressive disorder [@B31]. The effect of rs1800497 on DRD2 binding in UCC patients versus healthy subjects remains unclear and is worthy of further investigation. Classically, the dopamine-DRD2 axis was thought of in terms of antagonism of cAMP-dependent signaling, where G~αi~ subunits bind to and inhibit adenylyl cyclases and further suppress cAMP production and PKA activation [@B32]. The cAMP/PKA signaling pathway was reported to inhibit the invasive ability of bladder cancer cells [@B33], suggesting that DDR2 SNPs might affect the dopamine-DRD2 axis to further regulate its downstream cAMP/PKA signaling and modulate invasion of UCC.

It is well-known that smoking is one of the important risk factors for developing bladder cancer [@B34]. Previous SNP-related studies in UCC also showed significantly higher ratios of individuals with smoking behaviors than in the control group [@B35]. However, our study was not suitable for investigating the combined effect of tobacco carcinogen exposure and DRD2 SNPs on UCC susceptibility due to a bias in the ratio of individuals with a smoking habit among our recruited UCC patients. In our recruited cohort, there was a higher ratio of individuals with a smoking habit in the healthy control group than in the UCC group. Thus, more UCC patients with a smoking habit should be recruited to further explore the combined effect of DRD2 SNPs and tobacco carcinogen exposure on the susceptibility and progression of UCC.

In conclusion, in a Taiwanese population**,** we first identified that the DRD2 rs6277C/T genotype appeared to attenuate the risk of developing UCC. Female UCC patients harboring at least one DRD2 -141Del polymorphism more easily developed an advanced stage and larger tumors. UCC patients under the age of 65 years carrying at least one polymorphic T allele of DRD2 rs1800497 had a higher risk of developing muscle-invasive tumors. Ultimately, we propose that future work should focus on investigating the functional activities of these polymorphisms mentioned above and their effects on tumor progression, which would help us understand the underlying mechanisms of UCC development.
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![Clinical relevance of dopamine receptor D2 (DRD2) levels in bladder urothelial cell carcinoma (UCC) patients obtained from TCGA and GEO databases. A-C: DRD2 gene expression levels in bladder urothelial carcinoma tissues from TCGA were compared according to clinical stages (A), Tumor size status (T stages) (C), and metastasis status (M stages) (B). Statistical significance was analyzed by a *t*-test. \* *p*\<0.05. D: An overall survival curve was produced for patients with high (red lines) and low (blue lines) DRD2 expression levels using the Kaplan-Meier analysis. *p* values were determined using a log-rank test. E: Another UCC cohort from the GEO (GSE13507) was analyzed for the correlation between DRD2 expression levels and tumor invasive status. F: A Kaplan-Meier plot of disease-specific survival of 165 patients with bladder UCC (GSE13507) stratified by DRD2 expression. A log-rank test was used to examine between-group differences.](ijmsv15p1187g001){#F1}

###### 

Distributions of demographic characteristics of 369 patients with urothelial cell carcinoma (UCC)

  Variable                         Patients (N=369)
  -------------------------------- ------------------
                                   
  **Age (years)**                  **Mean ± S.D.**
                                   68.81 ± 11.77
  **Gender**                       
  Male                             241 (65.3%)
  Female                           128 (34.7%)
  **Tobacco consumption**          
  No                               257 (69.6%)
  Yes                              112 (30.4%)
  **Stage**                        
  Superficial tumor (pTa or pT1)   213 (57.7%)
  Invasive tumor (pT2\~pT4)        156 (42.3%)
  **Tumor T status**               
  T0-T2                            254 (68.8%)
  T3-T4                            115 (31.2%)
  **Lymph node status**            
  N0                               327 (88.6%)
  N1+N2                            42 (11.4%)
  **Metastasis**                   
  M0                               357 (96.7%)
  M1                               12 (3.3%)
  **Histopathologic grading**      
  Low grade                        51 (13.8%)
  High grade                       318 (86.2%)

###### 

Distribution frequency of *DRD2* genotypes in 738 controls and 369 UCC patients.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------
  Location         Variable            Controls (*N*=738) *n* (%)   Patients (*N*=369) *n* (%)   OR (95% CI)                   AOR (95% CI)
  ---------------- ------------------- ---------------------------- ---------------------------- ----------------------------- -----------------------------
  **Promoter**     **rs1799732**\                                                                                              
                   **-141C\>del**                                                                                              

                   Ins/Ins             597 (80.9%)                  303 (82.1%)                  1.00                          1.00

                   Ins/Del             133 (18.0%)                  62 (16.8%)                   0.918 (0.659\~1.280)          0.642 (0.383\~1.076)

                   Del/Del             8 (1.1%)                     4 (1.1%)                     0.985 (0.294\~3.298)          1.067 (0.209\~5.441)

                   Ins/Del + Del/Del   141 (19.1%)                  66 (17.9%)                   0.922 (0.667\~1.274)          0.665 (0.403\~1.095)

  \                **rs1079597**\                                                                                              
  **Intron 1**     **TaqIB**                                                                                                   

                   GG                  239 (32.4%)                  131 (35.5%)                  1.00                          1.00

                   GA                  381 (51.6%)                  172 (46.6%)                  0.824 (0.623\~1.089)          0.969 (0.655\~1.433)

                   AA                  118 (16.0%)                  66 (17.9%)                   1.020 (0.706\~1.476)          1.138 (0.686\~1.888)

                   GA+AA               499 (67.6%)                  238 (64.5%)                  0.870 (0.669\~1.132)          1.010 (0.698\~1.463)

  \                **rs6277**\                                                                                                 
  **Exon 7**       **957C\>T**                                                                                                 

                   CC                  646 (87.5%)                  339 (91.9%)                  1.00                          1.00

                   CT                  87 (11.8%)                   30 (8.1%)                    0.657 (0.425\~1.016)\         **0.405 (0.196\~0.837)\***\
                                                                                                 *p*=0.059                     ***p*=0.015**

                   TT                  5 (0.7%)                     0 (0%)                       \-\-\-\--                     \-\-\-\--

                   CT+TT               92 (12.5%)                   30 (8.1%)                    **0.621 (0.403\~0.958)\***\   **0.385 (0.187\~0.794)\***\
                                                                                                 ***p*=0.030**                 ***p*=0.010**

  **3\' UTR**\     **rs1800497**\                                                                                              
  **downstream**   **TaqIA**                                                                                                   

                   CC                  276 (37.4%)                  146 (39.6%)                  1.00                          1.00

                   CT                  359 (48.6%)                  162 (43.9%)                  0.853 (0.649\~1.121)          0.971 (0.661\~1.426)

                   TT                  103 (14.0%)                  61 (16.5%)                   1.120 (0.770\~1.629)          1.384 (0.839\~2.282)

                   CT+TT               462 (62.6%)                  223 (60.4%)                  0.912 (0.706\~1.179)          1.066 (0.744\~1.527)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------

The odds ratio (OR) with their 95% confidence intervals (CIs) were estimated by logistic regression models.

The adjusted OR (AOR) with their 95% CIs were estimated by multiple logistic regression models after controlling for age, sex, and tobacco consumption.

###### 

Distribution frequency of the clinical status and *DRD2* rs1800497 genotype frequencies in 124 younger patients with UCC (aged \<65 years)

                                   DRD2 (rs1800497)                                               
  -------------------------------- ------------------ -------------------- ---------------------- -----------------
  Variable                         CC (%) (*n*=45)    CT+TT (%) (*n*=79)   OR (95% CI)            *p* value
  **Stage**                                                                                       
  Superficial tumor (pTa or pT1)   30 (66.7%)         37 (46.8%)           1.00                   
  Invasive tumor (pT2\~pT4)        15 (33.3%)         42 (53.2%)           2.270 (1.060\~4.860)   ***p*=0.033\***
  **Tumor T status**                                                                              
  T0\~T2                           33 (73.3%)         52 (65.8%)           1.00                   
  T3 or T4                         12 (26.7%)         27 (34.2%)           1.428 (0.637\~3.203)   *p*=0.386
  **Lymph node status**                                                                           
  N0                               38 (84.4%)         66 (83.5%)           1.00                   
  N1+N2                            7 (15.6%)          13 (16.5%)           1.069 (0.393\~2.912)   *p*=0.896
  **Metastasis**                                                                                  
  M0                               45 (100%)          75 (94.9%)           1.00                   
  M1                               0 (0%)             4 (5.1%)             \-\--                  *p*=0.125
  **Histopathologic grading**                                                                     
  Low grade                        8 (17.8%)          9 (11.4%)            1.00                   
  High grade                       37 (82.2%)         70 (88.6%)           1.682 (0.599\~4.722)   *p*=0.320

###### 

Distribution frequency of the clinical status and *DRD2* rs1799732 genotype frequencies in 128 female patients with UCC.

                                   DRD2 (rs1799732)                                                           
  -------------------------------- -------------------- ------------------------------ ---------------------- -----------------
  Variable                         Ins/Wt (%) (n=102)   Ins/Del + Del/Del (%) (n=26)   OR (95% CI)            p value
  **Stage**                                                                                                   
  Superficial tumor (pTa or pT1)   63 (61.8%)           10 (38.5%)                     1.00                   
  Invasive tumor (pT2\~pT4)        39 (38.2%)           16 (61.5%)                     2.585 (1.066-6.264)    ***p*=0.032\***
  **Tumor T status**                                                                                          
  T0\~T2                           75 (73.5%)           13 (50.0%)                     1.00                   
  T3 or T4                         27 (26.5%)           13 (50.0%)                     2.778 (1.146-6.735)    ***p*=0.021\***
  **Lymph node status**                                                                                       
  N0                               93 (91.2%)           22 (84.6%)                     1.00                   
  N1+N2                            9 (8.8%)             4 (15.4%)                      1.879 (0.530-6.664)    *p*=0.323
  **Metastasis**                                                                                              
  M0                               100 (98.0%)          25 (96.2%)                     1.00                   
  M1                               2 (2.0%)             1 (3.8%)                       2.000 (0.174-22.949)   *p*=0.571
  **Histopathologic grading**                                                                                 
  Low grade                        12 (11.8%)           2 (7.7%)                       1.00                   
  High grade                       90 (88.2%)           24 (92.3%)                     1.600 (3.335-7.639)    *p*=0.553
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